Cencora, Inc. · NYSE:COR
Cencora — 42nd Annual J.P. Morgan Healthcare Conference (January 2024)
18 slides from Cencora's conference presentation, Jan 8, 2024
Slide 1: J.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference Steven H. Collis, Chairman, President, and CEO January 2024
Slide 2: Cautionary note regarding forward-looking statements
Cautionary note regarding forward-looking statements Certain of the statements contained in this presentation are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Securit
Slide 3: Cencora at a glance
Cencora at a glance 8% - 12%* targeted long- term adjusted diluted EPS growth *Growth rates given on a constant currency, ex-COVID basis. Uniting under our new identity as Cencora in 2023, Long-term vision of we are better positioned to expanding leadership grow globally and leverage and growing hig
Slide 4: Our customers
Our customers Partnership is at the core of our business. We work hand-in-hand with our customers to achieve their business goals and deliver healthcare excellence. Biopharma Specialty physician Health systems Pharmacy Animal health practices Companies that Interconnected networks Businesses respons
Slide 5: Connecting providers and biopharma manufacturers
Connecting providers and biopharma manufacturers Our scale, expertise, and extensive network of customers and partners allow us to play a key role in supporting pharma innovation across the value chain in the global geographies we serve Providers Biopharma manufacturers Patient experience solutions
Slide 6: U.S. Healthcare Solutions segment
U.S. Healthcare Solutions segment Leadership in human and animal health Segment growth drivers • Long-term strategic relationships with market-leading customers Foundational pharmaceutical in each channel distribution • Specialty distribution and commercialization services contributes to our value a
Slide 7: International Healthcare Solutions segment
International Healthcare Solutions segment Differentiated global platform offers broad and deep suite Segment growth drivers of innovative services • Leading pan-European wholesaler and related solutions provider Pan-European pharmaceutical • Innovative provider of upstream pharma manufacturer servi
Slide 8: Broad portfolio of leading specialty solutions
Broad portfolio of leading specialty solutions Robust suite of solutions to position Cencora as partner of choice Clinical and commercialization services Market access and regulatory Clinical trial support Data and analytics Pharmacovigilance Quality management affairs consulting and control Globall
Slide 9: Cencora financial highlights and guidance
Cencora financial highlights and guidance FY23 financial highlights $262.2B $3.3B $3.1B $11.99 revenue adjusted adjusted adjusted EPS(1) operating income(1) free cash flow(1) FY24 guidance and long-term growth targets(1) FY24 guidance Long-term targets Adjusted operating income 8% - 10%* 5% - 8%* Ad
Slide 10: Strong growth driven by execution and strategic capital deployment
Strong growth driven by execution and strategic capital deployment Adjusted EPS(1) Adjusted operating income(1) FY19-FY23 Cumulative 13% 5-year CAGR 11% 5-year CAGR Capital Deployment $3.29B $11.99 $3.16B $11.03 $9.26 $2.65B $7.90 $2.20B $7.09 $6.49 $2.05B $1.98B CapEx $2.1B M&A $8.2B(2) Share repur
Slide 11: Creating differentiated value for our stakeholders
Creating differentiated value for our stakeholders Our long-term, sustainable growth is supported by investments in our people and culture and commitment to ESG Our 5 Strategic Imperatives Why we exist We are united in our responsibility to create healthier futures Advance core business Enhance capa
Slide 12: FY23 strategic acquisitions and investments
FY23 strategic acquisitions and investments • Minority investment resulting in a 35% stake with the • Acquisition furthers our long-term leadership and growth in opportunity for full ownership in three to five years specialty services, a crucial strategic pillar for Cencora • Natural evolution of ou
Slide 13: Creating differentiated value for our stakeholders
Creating differentiated value for our stakeholders Our long-term, sustainable growth is supported by investments in our people and culture and commitment to ESG Our 5 Strategic Imperatives Why we exist We are united in our responsibility to create healthier futures Advance core business Enhance capa
Slide 14: Appendix
cencora Appendix
Slide 15: Adjusted diluted earnings per share
Adjusted diluted earnings per share Fiscal years ended September 30, 2018, through September 30, 2023 2023 2022 2021 2020 2019 2018 GAAP diluted EPS $8.53 $8.04 $7.39 ($16.65) $4.04 $7.53 Gains from antitrust litigation settlements (0.90) (0.01) (0.58) (0.03) (0.51) (0.12) LIFO 0.77 0.25 (0.70) 0.03
Slide 16: Adjusted operating income
Adjusted operating income Fiscal years ended September 30, 2018, through September 30, 2023 (in millions) 2023 2022 2021 2020 2019 2018 GAAP operating income (loss) $2,341 $2,366 $2,354 ($5,135) $1,112 $1,444 Gains from antitrust litigation settlements (239) (2) (169) (9) (146) (36) LIFO 205 67 (203
Slide 17: Contact
Contact Bennett S. Murphy Senior Vice President Head of Investor Relations & Treasury Bennett.Murphy@cencora.com 17
Slide 18: Thank you
Thank you
Cencora — 42nd Annual J.P. Morgan Healthcare Conference (January 2024) on 6ix